Phage Based Diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Menu
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us

New research explains MAP found in pasteurised milk

A new highly sensitive test has found 10 per cent of milk samples contain low levels of the pathogen, according to research due to published in Food Microbiology.
  • April 11, 2018
  • Johne's Disease, MAP, Milk Quality Assurance

The test Actiphage® was found to detect just 1-2 cells per 50ml, providing milk producers and processors the opportunity to further improve dairy quality assurances as part of production line processes.

MAP in 10% of retail samples

The phage-based assay, developed by PBD Biotech, found viable Mycobacterium avium subspecies paratuberculosis (MAP) in 10.3% of the 386 samples of retail purchased pasteurised milk tested.

Two-thirds of the MAP-positive samples (6.8%) contained just 1-2 detectable MAP cells per 50ml, with a further 1.1% containing more than 10 detectable MAP cells per 50ml.

In previous milk studies that used culture or PCR-based detection methods, it is unlikely that samples containing less than 100 MAP cells per 50ml would have been detected, explaining why this new more sensitive method found more MAP-positive samples.

Dr Ben Swift, corresponding author of the research and co-founder of PBD Biotech, said, “Dr Cath Rees and I discovered that using the Actiphage test mycobacteria cells could be rapidly detected in multiple sample types, such as blood and milk, at very high sensitivity and specificity.

“Additionally, the phage-based diagnostic can distinguish between viable and non-viable organisms. These research findings emphasise the important role that Actiphage can play within food manufacturing as part of quality assurance programmes, helping to continue building consumer confidence in our already-high standards.”

MAP implicated in human conditions

MAP causes Johne’s disease, a chronic wasting disease of cattle and other ruminants, which not only affects animal health but has a significant economic impact on the dairy industry hence the need for regular milk testing to detect and monitor herd-level infection.

MAP has also been implicated in the development of Crohn’s disease*, with the mycobacteria found in the bowel tissue of a proportion of patients with the condition. However, no causal relationship between MAP and the inflammatory bowel condition has been established.

Dr Berwyn Clarke, CEO of PBD Biotech, commented, “We now have a new research tool at our fingertips that can rapidly detect the presence of MAP in all tissue and fluid at very high sensitivity, providing a real opportunity to improve our understanding of this mycobacteria and its associated diseases.”

Shows for first time MAP shed from udder cells

Although many studies have shown that MAP can be detected in pasteurised milk, this new research reveals that, contrary to previous hypothesis, the mycobacteria was not introduced through poor hygiene standards and faecal contamination but was shed directly into the milk samples through somatic or ‘body’ cells within the cow’s udder.

The location of MAP internalised within somatic cells may explain why low-levels of the mycobacterium are protected against heat inactivation during pasteurisation.

There is no regulatory MAP count limit for milk or other dairy products however the new highly sensitive Actiphage assay, which delivers results in hours, rather than weeks, will enable producers and processors to more efficiently and effectively assess milk as part of the production line.

Given the rapidity of PBD Biotech’s assay and its critical specificity for live cells, there is the potential to perform a larger trial in order to ascertain the ability of this new phage-based method to monitor the efficacy of milk pasteurisation processes on a larger scale.

The phage-based assay has also been successfully used to detect viable MAP in raw milk, powdered infant formula, cheese and in the blood of infected animals.

To find out more about our Actiphage tests contact us.

References for the implication of MAP in the development of Crohn’s disease

Bull et al, 2003. Detection and verification of Mycobacterium avium subsp paratuberculosis in fresh ileocolonic mucosal biopsy specimens from individuals with and without Crohn’s disease. Journal of Clinical Microbiology, 41, 2915-2923

Feller et al, 2007. Mycobacterium avium subspecies paratuberculosis and Crohn’s disease: a systematic review and meta-analysis. Lancet Infectious Diseases. 7, 607-613

Rhodes et al, 2014. Mycobacterium avium Subspecies paratuberculosis: Human Exposure through Environmental and Domestic Aerosols. Pathogens. 3,557-595.

Share:

Related posts

Loading...
See PBD Biotech at The Dairy Show

5 October 2022

See us at The Dairy Show

September 6, 2022
Ensuring consumer confidence in dairy products has never been more vital and we are delighted to have the opportunity to talk about our new blood test and bulk milk test with producers, cheesemakers, dairy companies and others across the industry...
See PBD Biotech at The Dairy Show

5 October 2022

See us at The Dairy Show

September 6, 2022
Ensuring consumer confidence in dairy products has never been more vital and we are delighted to have the opportunity to...

Actiphage detects Johne’s disease in vaccinated goat

June 9, 2022
A study presented at ICP 2022 has shown that the blood test Actiphage is able to distinguish between goats that are naturally infected and those vaccinated against Mycobacterium avium subspecies paratuberculosis (MAP), the pathogen that causes Johne’s Disease, supporting the...

Actiphage detects Johne’s disease in vaccinated goat

June 9, 2022
A study presented at ICP 2022 has shown that the blood test Actiphage is able to distinguish between goats that...
bison MAP diagnostic

Actiphage identifies strain of mycobacteria in blood of bison

May 26, 2022
Results presented at ICP (12-16th June) from first study in North American bison, shows capacity of Actiphage to sub-type mycobacteria in blood.
bison MAP diagnostic

Actiphage identifies strain of mycobacteria in blood of bison

May 26, 2022
Results presented at ICP (12-16th June) from first study in North American bison, shows capacity of Actiphage to sub-type mycobacteria...
cow

Why breakthrough human trials of Actiphage are good news for farmers

May 12, 2022
The findings are a real breakthrough for animal diagnosis as it provides clinical evidence that detection of low levels of mycobacteria in the blood is an indication that the animal is infected and has the potential to develop disease.
cow

Why breakthrough human trials of Actiphage are good news for farmers

May 12, 2022
The findings are a real breakthrough for animal diagnosis as it provides clinical evidence that detection of low levels of...
1 2 3 Next »

developers of phage-based diagnostics

Contact Us

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!
PBD Biotech

More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB

Read More
PBD Biotech

Delighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies

Read More
PBD Biotech

Testing 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease

Read More